Jean-Marie Cuillerot

Jean-Marie Cuillerot, M.D., is Chief Medical Officer at Acrivon Therapeutics, Inc. Jean-Marie was previously the Chief Medical Officer at Dragonfly Therapeutics where he established and led a clinical team advancing multiple potential first-in-class assets. Prior to Dragonfly, Jean-Marie was the chief medical officer of Agenus, where he led development activities for five investigational therapies. At EMD Serono, an affiliate of Merck Serono, Jean-Marie served as the global head of clinical development in immuno-oncology (IO) and as the vice president of clinical immunotherapy/IO. He oversaw the company’s IO portfolio which included two checkpoint inhibitors and two immuno-cytokines. Notably, Jean-Marie led the clinical development of avelumab, the first drug approved to treat Merkel cell carcinoma and second-line bladder cancer, from pre-IND though global submissions in record time, an achievement that earned him the Merck CEO Award. From 2007 to 2012, he was at Bristol- Myers Squibb, where he was medical lead for the life cycle management of ipilimumab, an anti-CTLA-4 antibody and the world’s first immune checkpoint therapy for cancer, where he designed and led Phase 2 and Phase 3 studies across multiple indications and supported regulatory filings in the United States and Europe. Earlier in his career, Jean-Marie also served in clinical development at Novartis, as a clinical research physician at the Centre d’Immunologie Pierre Fabre, and as an assistant professor at the Hôpitaux Universitaires de Strasbourg. Jean-Marie received a B.S. in biochemistry, an M.Sc. in cellular and molecular biology and an M.D. at the University Louis Pasteur (Strasbourg, France).

Jeremy Barton

Jeremy Barton, M.D. is Chief Medical Advisor at Acrivon Therapeutics, Inc. Jeremy has over 29 years of experience in all phases of oncology drug development in the pharmaceutical industry in Switzerland, UK and currently in the US. Most recent industry responsibilities have included Chief Medical Officer roles at Biogen Idec, eFFECTOR Therapeutics and Mirati Therapeutics. He was also head of early Oncology Development at Pfizer for 5 years overseeing the transition of all Oncology compounds from research through IND to proof-of-concept studies.

After obtaining a Master’s degree in Physiology from Oxford University and his M.D. degree at University College Hospital Medical School in London, he trained in Internal Medicine and Clinical Oncology in the United Kingdom and practiced for 11 years in the National Health Service. Jeremy is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of Faculty of Pharmaceutical Medicine.

Jung-Min Lee

Suspendisse et mi vitae nisi condimentum vulputate. Interdum et malesuada fames ac ante ipsum primis in faucibus. Phasellus sed nisl vel leo egestas finibus ac a enim. Vestibulum varius eu nunc quis lacinia. Sed accumsan urna sed odio convallis, vitae malesuada enim bibendum. Pellentesque imperdiet posuere congue. Etiam tortor turpis, porta sed posuere quis, fringilla vel felis. Quisque et varius tellus. Vestibulum tortor tellus, suscipit eu tempus sit amet, facilisis nec lectus. Nunc urna ipsum, finibus at placerat at, facilisis ac tortor. In hac habitasse platea dictumst. Vestibulum venenatis et risus et pretium.